Abl­ynx IPO rais­es $200M for its nanobody plat­form ef­fort

Bel­gian biotech Abl­ynx has low­ered its share price but up­sized the num­ber of shares on of­fer in its US IPO, rais­ing $200 mil­lion from its de­but. And an­oth­er $29 mil­lion could fol­low if the un­der­writ­ers pick up their al­lot­ment of 1.7 mil­lion shares at the $17.50 price.

Abl­ynx had pen­cilled in a $150 mil­lion tar­get when it filed the IPO at the be­gin­ning of this month. But these can be fast-mov­ing fig­ures these days as a long queue of biotechs turn to an ea­ger in­vestor group for more funds to do de­vel­op­ment work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.